Mateo Aboy

LML, University of Cambridge

Principal Research Scholar (PRA) in Biomedical Innovation, Precision Medicine, AI & Law

Trinity Ln

Cambridge, CB2 1TN

United Kingdom

http://www.lml.law.cam.ac.uk/people/Research-Scholars-Associates/Prof-mateo-aboy

SCHOLARLY PAPERS

18

DOWNLOADS

1,696

SSRN CITATIONS

8

CROSSREF CITATIONS

3

Scholarly Papers (18)

1.

COVID-19 Contact Tracing Apps: A Stress Test for Privacy, the GDPR and Data Protection Regimes

Journal of Law and the Biosciences (2020), University of Cambridge Faculty of Law Research Paper No. 23/2020
Number of pages: 21 Posted: 03 Jun 2020
University of Cambridge - Faculty of Law, LML, University of Cambridge and University of Cambridge - Faculty of Law
Downloads 715 (49,727)
Citation 3

Abstract:

Loading...

data privacy, information privacy, GDPR, HIPAA, COVID-19, contact tracing, data protection

2.

Cross-Border Transfers of Personal Data after Schrems II: Supplementary Measures and New Standard Contractual Clauses (SCCs)

Number of pages: 12 Posted: 27 Oct 2021
Centre for Advanced Studies in Biomedical Innovation Law (CeBIL), Faculty of Law, University of Copenhagen, LML, University of Cambridge and University of Copenhagen - Centre for Advanced Studies in Biomedical Innovation Law (CeBIL) - Faculty of Law
Downloads 398 (102,314)

Abstract:

Loading...

Schrems II, international data transfers, supplementary measures, new Standard Contractual Clauses (SCCs), EDPB Recommendations 01/2020, encryption, security and organisational measures, GDPR.

3.

The Effects of Myriad and Mayo on Molecular Test Development in the US and Europe: Interviews from the Frontline

22 Vanderbilt Journal of Entertainment & Technology Law 785, University of Cambridge Faculty of Law Research Paper 33/2019
Number of pages: 53 Posted: 29 May 2019 Last Revised: 21 May 2020
University of Cambridge - Faculty of Law, University of Cambridge - Faculty of Law and LML, University of Cambridge
Downloads 111 (330,319)

Abstract:

Loading...

patent, patentable subject matter, patent eligibility, 35 USC 101, US, Europe, interviews, empirical, comparative

4.

Lost on the High Seas without a Safe Harbor or a Shield? Navigating Cross-Border Data Transfers in the Pharmaceutical Sector After Schrems II Invalidation of the EU-US Privacy Shield

European Pharmaceutical Law Review (EPLR), 4(3):153-160
Number of pages: 10 Posted: 28 Jan 2021 Last Revised: 10 Apr 2021
Centre for Advanced Studies in Biomedical Innovation Law (CeBIL), Faculty of Law, University of Copenhagen, University of Copenhagen - Centre for Advanced Studies in Biomedical Innovation Law (CeBIL) - Faculty of Law, University of Ghent, Faculty of Law and LML, University of Cambridge
Downloads 104 (345,126)

Abstract:

Loading...

GDPR, Data transfer, Schrems II case, data protection, data security, Privacy Shield, Standard Contractual Clauses (SCCs), pharmaceutical sector

5.

Supplementary Measures and Appropriate Safeguards for International Transfers of Personal Data after Schrems II

Number of pages: 27 Posted: 06 Apr 2022
Centre for Advanced Studies in Biomedical Innovation Law (CeBIL), Faculty of Law, University of Copenhagen, Kyushu University - Graduate School of Law, LML, University of Cambridge and University of Copenhagen - Centre for Advanced Studies in Biomedical Innovation Law (CeBIL) - Faculty of Law
Downloads 88 (383,692)

Abstract:

Loading...

International transfers, cross-border transfers of personal data, homomorphic encryption (HE), multiparty processing, new standard contractual clauses (SCCs), Schrems II, supplementary measures, appropriate safeguards

6.

Myriad's Impact on Gene Patents

Nature Biotechnology, Vol. 34, No. 11, p. 1119-1123, Nov. 2016, University of Cambridge Faculty of Law Research Paper No. 58/2017
Number of pages: 8 Posted: 04 Aug 2017 Last Revised: 25 Jun 2019
LML, University of Cambridge, University of Cambridge - Faculty of Law, University of Cambridge - Faculty of Law and University of Cambridge
Downloads 80 (405,895)
Citation 1

Abstract:

Loading...

Patents, BRCA, Myriad, Gene Patents, Patent Publications, Empirical Analysis

7.

After Myriad, What Types of Claim Amendments Change a Patent Ineligible Isolated Gene Claim Into an Eligible Patent Claim That Is ‘Markedly Different’ From Nature?

35 Nature Biotechnology 820-825
Number of pages: 31 Posted: 22 May 2018
LML, University of Cambridge, University of Cambridge - Faculty of Law, University of Cambridge - Faculty of Law, University of Cambridge - Faculty of Law and University of Cambridge
Downloads 60 (472,578)
Citation 1

Abstract:

Loading...

Patents, Patent Law, Biotechnology, Myriad, Gene Patents, US, Empirical Legal Research

8.

Response to USPTO’s Patent Eligibility Jurisprudence Study (Docket No.: PTO–P–2021–0032)

Number of pages: 155 Posted: 11 Oct 2021
LML, University of Cambridge, University of Cambridge - Faculty of Law, University of Cambridge, University of Cambridge - Faculty of Law and University of Cambridge - Faculty of Law
Downloads 38 (569,923)

Abstract:

Loading...

Patentable subject matter, Bilski, Mayo, Myriad, Alice, USPTO, empirical studies, innovation, diagnostics, gene patents, software

9.

Was the Myriad Decision a ‘Surgical Strike’ on Isolated DNA Patents, or Does it Have Wider Impacts?

36(12) Nature Biotechnology 1146
Number of pages: 6 Posted: 27 Jun 2019 Last Revised: 18 Sep 2019
LML, University of Cambridge, University of Cambridge, University of Cambridge - Faculty of Law, University of Cambridge - Faculty of Law and University of Cambridge - Faculty of Law
Downloads 35 (586,126)
Citation 1

Abstract:

Loading...

patents, gene patents, Myriad, wider impacts, DNA, markedly different, naturally occurring compounds, empirical, Biotechnology, US

10.

Has the EU Incentive for Drug Repositioning Been Effective? An Empirical Analysis of the '+1' Regulatory Exclusivity

52(7) International Review of Intellectual Property and Competition Law 825
Number of pages: 27 Posted: 31 Aug 2021
University of Cambridge - Faculty of Law, University of Cambridge - Faculty of Law, LML, University of Cambridge and Centre for Advanced Studies in Biomedical Innovation Law (CeBIL)
Downloads 32 (602,920)

Abstract:

Loading...

drug repositioning, regulatory exclusivities, patents, empirical study, intellectual property

11.

Continental Drift? Do European Clinical Genetic Testing Laboratories Have a Patent Problem?

European Journal of Human Genetics, 2019, University of Cambridge Faculty of Law Research Paper 32/2019
Number of pages: 12 Posted: 01 Apr 2019 Last Revised: 31 Oct 2019
University of Cambridge - Faculty of Law, University of Cambridge - Faculty of Law, Unversity of Cambidge, King’s College London, Dept of Social Science, Health & Medicine, LML, University of Cambridge, University of Tasmania, European Molecular Genetics Quality Network and University of Sussex
Downloads 27 (634,002)

Abstract:

Loading...

patents, genetic tests, Europe, patent law

12.

Reply to C.D. Richter

European Journal of Human Genetics
Number of pages: 5 Posted: 24 May 2021
University of Cambridge - Faculty of Law, University of Cambridge - Faculty of Law, Unversity of Cambidge, King’s College London, Dept of Social Science, Health & Medicine, LML, University of Cambridge, University of Tasmania, European Molecular Genetics Quality Network and University of Sussex
Downloads 8 (784,324)

Abstract:

Loading...

patents, genetic testing, Europe

13.

The FDA De Novo Medical Device Pathway, Patents, and Anticompetition

Nature Biotechnology, vol. 38, 2020, pp. 1028–1029, University of Illinois College of Law Legal Studies Research Paper No. 21-24
Posted: 09 Aug 2021
Jacob S. Sherkow and Mateo Aboy
University of Illinois College of Law and LML, University of Cambridge

Abstract:

Loading...

patents, FDA, De Novo, 510(k), anticompetition, regulation, medical devices

14.

Mayo’s Impact on Patent Applications Related to Biotechnology, Diagnostics and Personalized Medicine

Mayo’s impact on patent applications related to biotechnology, diagnostics and personalized medicine. / Aboy, Mateo; Crespo, Cristina; Liddell, Kathleen; Minssen, Timo; Liddicoat, Johnathan, Nature Biotechnology, Vol. 37, 05.2019, p. 513-518.
Posted: 18 Aug 2020
LML, University of Cambridge, University of Cambridge, University of Cambridge - Faculty of Law, University of Copenhagen - Centre for Advanced Studies in Biomedical Innovation Law (CeBIL) - Faculty of Law and University of Cambridge - Faculty of Law

Abstract:

Loading...

15.

One Year After Vanda, Are Diagnostics Patents Transforming Into Methods of Treatment to Overcome Mayo-Based Rejections?

One year after Vanda, are diagnostics patents transforming into methods of treatment to overcome Mayo-based rejections? / Aboy, Mateo; Crespo, Cristina; Liddell, Kathleen ; Davey, Neal; Liddicoat, Johnathan; Minssen, Timo., Nature Biotechnology, Vol. 38, 09.03.2020, p. 279–283.
Posted: 18 Aug 2020
LML, University of Cambridge, University of Cambridge, University of Cambridge - Faculty of Law, affiliation not provided to SSRN, University of Cambridge - Faculty of Law and University of Copenhagen - Centre for Advanced Studies in Biomedical Innovation Law (CeBIL) - Faculty of Law

Abstract:

Loading...

16.

How Does Emerging Patent Case Law in the US and Europe Affect Precision Medicine? How Will Today’s Patent Law Affect Tomorrow’s Innovation in the Areas of Biomarkers and Nature-Based Products; Diagnostics; and Algorithms, Big Data and AI?

Aboy, M., Liddell, K., Crespo, C. et al. How does emerging patent case law in the US and Europe affect precision medicine?. Nat Biotechnol 37, 1118–1125 (2019)
Posted: 18 Aug 2020
LML, University of Cambridge, Harvard Law School, University of Cambridge - Faculty of Law, University of Cambridge - Faculty of Law, University of Cambridge, Pennsylvania State University, Dickinson Law and University of Copenhagen - Centre for Advanced Studies in Biomedical Innovation Law (CeBIL) - Faculty of Law

Abstract:

Loading...

17.

The EU-US Privacy Shield Regime for Cross- Border Transfers of Personal Data under the GDPR: What are the legal challenges and how might these affect cloudbased technologies, big data, and AI in the medical sector?

Lexxion, 2020
Posted: 14 Aug 2020
University of Copenhagen - Centre for Advanced Studies in Biomedical Innovation Law (CeBIL) - Faculty of Law, University of Ghent, Faculty of Law, LML, University of Cambridge and Centre for Advanced Studies in Biomedical Innovation Law (CeBIL), Faculty of Law, University of Copenhagen

Abstract:

Loading...

18.

Regulatory Responses to Medical Machine Learning

Journal of Law and the Biosciences, Volume 7, Issue 1, January-June 2020, lsaa002, https://doi.org/10.1093/jlb/lsaa002
Posted: 14 Aug 2020 Last Revised: 07 Jul 2021
University of Copenhagen - Centre for Advanced Studies in Biomedical Innovation Law (CeBIL) - Faculty of Law, Pennsylvania State University, Dickinson Law, LML, University of Cambridge, University of Michigan Law School and Harvard Law School

Abstract:

Loading...

Medical Devices, Artificial Intelligence, Regulation